Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1995-7-19
|
| pubmed:abstractText |
Clinical safety and efficacy of the new third-generation implantable cardioverter defibrillator (ICD) Ventak PRxII was studied in 50 patients (pts) with ventricular tachycardia (VT) and/or fibrillation (VF). In 23 pts (46%) the ICD was implanted with a transvenous lead system as first implant and 27 pts (54%) received the Ventak PRxII as generator replacement. Intraoperatively, the mean defibrillation threshold (DFT) was 13 +/- 8 joules and 12 +/- 8 joules, respectively. One pt died perioperatively. During a follow-up of 5.3 +/- 3.8 months 3 patients died due to heart failure. During follow-up 1060 arrhythmia episodes (AE) occurred and were terminated primarily by countershock in 121 AE (11%). Antitachycardia pacing (ATP) was tried in 939 AE (89%) and was successful in 878 AE (94%). Acceleration was present in 6 AE (< 1%). We conclude that there is a high efficacy rate in AE termination by the Ventak PRxII, using ATP or countershock. Therefore, the Ventak PRxII allows a flexible approach to cardiac rhythm management.
|
| pubmed:language |
ger
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0300-5860
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
84
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
275-83
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7785299-Adult,
pubmed-meshheading:7785299-Aged,
pubmed-meshheading:7785299-Aged, 80 and over,
pubmed-meshheading:7785299-Defibrillators, Implantable,
pubmed-meshheading:7785299-Electrocardiography,
pubmed-meshheading:7785299-Equipment Design,
pubmed-meshheading:7785299-Equipment Safety,
pubmed-meshheading:7785299-Female,
pubmed-meshheading:7785299-Follow-Up Studies,
pubmed-meshheading:7785299-Heart Ventricles,
pubmed-meshheading:7785299-Hemodynamics,
pubmed-meshheading:7785299-Humans,
pubmed-meshheading:7785299-Male,
pubmed-meshheading:7785299-Middle Aged,
pubmed-meshheading:7785299-Prospective Studies,
pubmed-meshheading:7785299-Tachycardia, Ventricular,
pubmed-meshheading:7785299-Treatment Outcome,
pubmed-meshheading:7785299-Ventricular Fibrillation
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
[Experiences with the new cardioverter-defibrillator Ventak PRxII].
|
| pubmed:affiliation |
Abteilung Kardiologie, Medizinische Hochschule Hannover.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|